Jasper Therapeutics Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
22
- Stock Symbol
-
JSPR
- Investments
-
2
- Share Price
-
$13.37
- (As of Thursday Closing)
Jasper Therapeutics General Information
Description
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
Contact Information
Website
www.jaspertx.comCorporate Office
- 2200 Bridge Parkway
- Suite 102
- Redwood City, CA 94065
- United States
Corporate Office
- 2200 Bridge Parkway
- Suite 102
- Redwood City, CA 94065
- United States
Jasper Therapeutics Stock Performance
As of 12-Nov-2026, Jasper Therapeutics’s stock price is $13.37. Its current market cap is $14.8M with 1.11M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $13.37 | $14.76 | $9.45 - $72.60 | $14.8M | 1.11M | 18.4K | -$47.70 |
Jasper Therapeutics Financials Summary
As of 30-Jun-2026, Jasper Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (1,595) | 2,015 | 230,296 | (12,820) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (32,136) | (76,442) | (74,927) | (68,556) |
| Net Income | (31,771) | (75,801) | (71,269) | (64,465) |
| Total Assets | 11,802 | 35,779 | 79,899 | 94,892 |
| Total Debt | 270 | 1,235 | 1,813 | 2,786 |
Jasper Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Jasper Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Jasper Therapeutics Comparisons
Industry
Financing
Details
Jasper Therapeutics Competitors (77)
One of Jasper Therapeutics’s 77 competitors is Vor Biopharma, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vor Biopharma | Formerly VC-backed | Boston, MA | ||||
| Lyell Immunopharma | Formerly VC-backed | South San Francisco, CA | ||||
| Fate Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Allogene Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Arvinas | Formerly VC-backed | New Haven, CT |
Jasper Therapeutics Patents
Jasper Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026151810-A1 | Methods for treating mast cell disorders with anti-cd117 antibodies | Pending | 07-Jan-2025 | ||
| JP-2026535602-A | Compositions and methods for depleting mast cells | Pending | 09-Oct-2023 | ||
| AU-2024357744-A1 | Compositions and methods for depletion of mast cells | Pending | 09-Oct-2023 | ||
| EP-4791431-A1 | Compositions and methods for depletion of mast cells | Pending | 09-Oct-2023 | ||
| WO-2025080714-A1 | Compositions and methods for depletion of mast cells | Inactive | 09-Oct-2023 | C07K16/2803 |
Jasper Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Jasper Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Jasper Therapeutics Acquisitions (2)
Jasper Therapeutics’s most recent deal was a Merger/Acquisition with Kira Pharma. The deal was made on 16-Jul-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Kira Pharma | 16-Jul-2026 | Merger/Acquisition | Drug Discovery | ||
| Amplitude Healthcare Acquisition | 24-Sep-2021 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
Jasper Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Jasper Therapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Kira Pharma | Suzhou, China | 2017 |
Jasper Therapeutics FAQs
-
When was Jasper Therapeutics founded?
Jasper Therapeutics was founded in 2018.
-
Where is Jasper Therapeutics headquartered?
Jasper Therapeutics is headquartered in Redwood City, CA.
-
What is the size of Jasper Therapeutics?
Jasper Therapeutics has 22 total employees.
-
What industry is Jasper Therapeutics in?
Jasper Therapeutics’s primary industry is Biotechnology.
-
Is Jasper Therapeutics a private or public company?
Jasper Therapeutics is a Public company.
-
What is Jasper Therapeutics’s stock symbol?
The ticker symbol for Jasper Therapeutics is JSPR.
-
What is the current stock price of Jasper Therapeutics?
As of 12-Nov-2026 the stock price of Jasper Therapeutics is $13.37.
-
What is the current market cap of Jasper Therapeutics?
The current market capitalization of Jasper Therapeutics is $14.8M.
-
Who are Jasper Therapeutics’s competitors?
Vor Biopharma, Lyell Immunopharma, Fate Therapeutics, Allogene Therapeutics, and Arvinas are some of the 77 competitors of Jasper Therapeutics.
-
What is Jasper Therapeutics’s annual earnings per share (EPS)?
Jasper Therapeutics’s EPS for 12 months was -$47.70.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
